Xenothera
Business Services · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
21 Rue La Nouë De Fer, Nantes, Pays de l...Phone Number
+33 240412987Website
www.xenothera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Xenothera
XENOTHERA is a biotechnology company specializing in innovative immunological treatments through its glyco humanized antibody platform. The company focuses on developing products for oncology and is actively involved in clinical trials, allowing eligible patients to participate. With a commitment to breakthrough medical innovations, XENOTHERA collaborates with first-class partners across France and Europe. Their mission emphasizes rapid development and responsiveness in the healthcare sector.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xenothera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Xenothera launches new products
Check out if Xenothera is spiking on competitors!
Xenothera, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Xenothera had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Xenothera has new funding data
Check if Xenothera has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Xenothera recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Xenothera
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Xenothera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Xenothera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Xenothera.
Xenothera Tech Stack
A closer look at the technologies used by Xenothera
Xenothera News & Media
XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1
NANTES, France--(BUSINESS WIRE)--In the context of a major resurgence of the COVID epidemic, the French biotech XENOTHERA announces recent data in favor of the strong interest of its glyco-humanized polyclonal antibody (GH-pAb) XAV-19 to treat patients in the initial viral phase of the disease. Several neutralization assays carried out by XENOTHERA have supplemented data already published (Vanhove et al. 2020, 2021, 2022). XAV-19 exhibits a strong neutralization activity against all omicron varResumen: XENOTHERA, junto con su socio Excelya, anuncia la inscripción del primer paciente en el ensayo clínico EUROXAV de su tratamiento anti-COVID, XAV-19
NANTES, Francia & BOULOGNE-BILLANCOURT, Francia--(BUSINESS WIRE)--La empresa de biotecnología XENOTHERA está iniciando el ensayo clínico europeo de su tratamiento para la COVID, XAV-19. El laboratorio de Nantes es el patrocinador del ensayo denominado EUROXAV, que será llevado a cabo por Excelya, una organización de investigación por contrato(CRO en sus siglas en inglés)líder en Europa. EUROXAV es un ensayo multicéntrico y aleatorizado de fase III en el que participarán 722 pacientes con COVIDXENOTHERA und sein Partner Excelya melden die Aufnahme des ersten Patienten in die klinische Studie EUROXAV zur Behandlung von COVID mit dem Medikament XAV-19
NANTES, Frankreich & BOULOGNE-BILLANCOURT, Frankreich--(BUSINESS WIRE)--Das Biotech-Unternehmen XENOTHERA hat eine europäische klinische Studie für die Behandlung mit seinem Medikament gegen COVID, XAV-19, gestartet. Das Labor aus Nantes ist der Sponsor der Studie EUROXAV, die von Excelya, einem führenden, auf klinische Forschung spezialisierten europäischen Auftragsforschungsinstitut (CRO) durchgeführt wird. Für die multizentrische, doppelblinde Phase-III-Studie EUROXAV werden 722 COVID-PatienXENOTHERA And Its Partner Excelya Announce the Recruitment of the First Patient in The EUROXAV Clinical Trial of its COVID Treatment XAV-19
NANTES, France & BOULOGNE-BILLANCOURT, France--(BUSINESS WIRE)--The biotech company XENOTHERA has begun the European clinical trial of its anti-COVID treatment, XAV-19. The Nantes laboratory is the sponsor of the trial, called EUROXAV, which will be carried out by Excelya, a leading European contract research organization (CRO) specializing in clinical research. EUROXAV is a multi-center, double-blind phase III trial that will recruit 722 patients with moderate COVID, hospitalized or monitored
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xenothera
Sign Up For FreeTo access detailed company insights
XENOTHERA is a biotechnology company specializing in innovative immunological treatments through its glyco humanized antibody platform. The company focuses on developing products for oncology and is actively involved in clinical trials, allowing eligible patients to participate. With a commitment to breakthrough medical innovations, XENOTHERA colla... Read More
